Sylvain Garciaz

Identifiants chercheurs

IdHAL :

sylvain-garciaz

ORCID :

0000-0002-0081-1255

ResearcherID :

http://www.researcherid.com/rid/AGJ-6731-2022

Présentation

Assistant Professor (Hematology / CRCM-Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes)

Publications

Article dans une revue (23)

Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1 Sylvain Garciaz,Camille Montersino,Maxence Bourgoin,Arnaud Jacquel,Rémy Castellanoet al. British Journal of Haematology, 2025, 207 (2), pp.381-386. ⟨10.1111/bjh.20195⟩ Article dans une revue hal-05575967v1
Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia Guillaume Berton,Marie‐anne Hospital,Sylvain Garciaz,Camille Rouzaud,Valerio Maisanoet al. European Journal of Haematology, 2025, 114 (4), pp.679-689. ⟨10.1111/ejh.14366⟩ Article dans une revue hal-05578020v1
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC ‐ DATAML ‐ MSKCC Retrospective Study Cassandre Petit,Jules Higue,Ziyad Acheaibi,Julia Gilhodes,Marie‐anne Hospitalet al. American Journal of Hematology, 2025, 100 (5), pp.906-908. ⟨10.1002/ajh.27626⟩ Article dans une revue hal-05578042v1
Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo Mael Heiblig,Pierre Peterlin,Stéphane Morisset,Pierre-Yves Dumas,Marie Sebertet al. Blood, 2025, 146 (Supplement 1), pp.3455-3455. ⟨10.1182/blood-2025-3455⟩ Article dans une revue hal-05413650v1
Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo Pierre Peterlin,Mael Heiblig,Stéphane Morisset,Sarah Bertoli,Marie Sebertet al. Blood, 2025, 146 (Supplement 1), pp.1658-1658. ⟨10.1182/blood-2025-1658⟩ Article dans une revue hal-05413216v1
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment Sylvain Garciaz,Pierre‐yves Dumas,Sarah Bertoli,David Sallman,Justine Decroocqet al. American Journal of Hematology, 2024, 99 (10), pp.1870-1876. ⟨10.1002/ajh.27417⟩ Article dans une revue hal-04916306v1
Venetoclax Resistance in Acute Myeloid Leukemia Sylvain Garciaz,Marie-Anne Hospital,Yves Collette,Norbert Vey Cancers, 2024, 16 (6), pp.1091. ⟨10.3390/cancers16061091⟩ Article dans une revue hal-04945122v1
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1 -mutant AML Jan Philipp Bewersdorf,Shai Shimony,Rory Shallis,Yiwen Liu,Guillaume Bertonet al. Blood Advances, 2024, 8 (18), pp.4845-4855. ⟨10.1182/bloodadvances.2024012858⟩ Article dans une revue hal-05141669v1
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death Sylvain Garciaz,Andrew Guirguis,Sebastian Müller,Fiona Brown,Yih-Chih Chanet al. Cancer Discovery, 2023 Article dans une revue hal-05344093v1
Downregulation of stromal syntenin sustains AML development Raphael Leblanc,Rania Ghossoub,Armelle Goubard,Rémy Castellano,Joanna Fareset al. EMBO Molecular Medicine, 2023, 15 (11), ⟨10.15252/emmm.202317570⟩ Article dans une revue hal-04532862v1
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome Samia Harbi,Louison Brac de la Perriere,Benjamin Bouchacourt,Sylvain Garciaz,Thomas Pagliardiniet al. Bone Marrow Transplantation, 2023, 59 (1), pp.101-106. ⟨10.1038/s41409-023-02134-w⟩ Article dans une revue hal-04957221v1
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients Sylvain Garciaz,Marie-Anne Hospital,Anne-Sophie Alary,Colombe Saillard,Yosr Hicheriet al. Cancers, 2022, 14 (8), pp.2025. ⟨10.3390/cancers14082025⟩ Article dans une revue hal-03665761v1
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study Domitille Costes-Tertrais,Thomas Hueso,Thomas Gastinne,Catherine Thieblemont,Lucie Obericet al. Bone Marrow Transplantation, 2022, 57 (4), pp.627-632. ⟨10.1038/s41409-022-01596-8⟩ Article dans une revue hal-03608256v1
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights J.E. Martin,S. Khalife-Hachem,T. Grinda,M. Kfoury,S. Garciazet al. Annals of Oncology, 2021, 32 (8), pp.1046-1048. ⟨10.1016/j.annonc.2021.04.015⟩ Article dans une revue hal-03376715v1
Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF Sylvain Garciaz,Patrick Sfumato,Angela Granata,Anne-Marie Imbert,Claire Fournelet al. PLoS ONE, 2020, 15 (3), pp.e0228878. ⟨10.1371/journal.pone.0228878⟩ Article dans une revue inserm-02526607v1
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers Thomas Hueso,Thomas Gastinne,Sylvain Garciaz,Emmanuelle Tchernonog,Caroline Deletteet al. Bone Marrow Transplantation, 2020, 55 (6), pp.1076-1084. ⟨10.1038/s41409-020-0783-y⟩ Article dans une revue hal-02500667v1
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation Sylvain Garciaz,Lia N’guyen Dasi,Pascal Finetti,Christine Chevalier,Julien Vernereyet al. Clinical Epigenetics, 2019, 11 (1), ⟨10.1186/s13148-019-0738-6⟩ Article dans une revue hal-02322283v1
Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity Myriam Koubi,Mathilde Poplineau,Julien Vernerey,Lia N 'Guyen,Guillaume Tiberiet al. Nucleic Acids Research, 2018, 46 (7), pp.3339-3350. ⟨10.1093/nar/gky080⟩ Article dans une revue hal-01765664v1
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers Cédric Rossi,Julia Gilhodes,Marie Maerevoet,Charles Herbaux,Franck Morschhauseret al. American Journal of Hematology, 2018, 93 (8), pp.1042-1049. ⟨10.1002/ajh.25154⟩ Article dans une revue hal-02050402v1
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers Sylvain Chantepie,Sylvain Garciaz,Emmanuelle Tchernonog,Frederic Peyrade,Marie-Virginie Larcheret al. American Journal of Hematology, 2018, 93 (6), pp.729 - 735. ⟨10.1002/ajh.25077⟩ Article dans une revue hal-01860419v1
Patients’ Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings Restivo Lea,Thémis Apostolidis,Anne Deborah Bouhnik,Sylvain Garciaz,Thérèse Aurranet al. PLoS ONE, 2016, ⟨10.1371/journal.pone.0154969⟩ Article dans une revue hal-01457098v1
Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites Emilie Mamessier,C. Drevet,F. Broussais-Guillaumot,M.-L. Mollichella,S. Garciazet al. Haematologica, 2015, 100 (4), pp.e155-e157. ⟨10.3324/haematol.2014.115782⟩ Article dans une revue hal-03606410v1
Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites Emilie Mamessier,Charlotte Drevet,Florence Broussais-Guillaumot,Marie-Laure Mollichella,Sylvain Garciazet al. Haematologica, 2015, 100, pp.E155-E157 Article dans une revue hal-01216319v1

Communication dans un congrès (2)

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia Naval Daver,Anjali Advani,Adolfo de la Fuente Burguera,Pau Montesinos,Sylvain Garciazet al. 67th ASH Annual Meeting, Dec 2025, Orlando, United States. pp.651-651, ⟨10.1182/blood-2025-651⟩ Communication dans un congrès hal-05592656v1
The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy Sarah Bertoli,Niklas Landberg,Emilie Bérard,Camille Gondran,Laetitia Largeaudet al. 67th ASH Annual Meeting, Dec 2025, Orlando, United States. pp.991-991, ⟨10.1182/blood-2025-991⟩ Communication dans un congrès hal-05413744v1

Poster de conférence (1)

Deciphering EZH2 Non-Canonical Activities in AML Resistance Lia N'Guyen,Emeline Boet,Camille Montersino,Claire Burny,Stéphane Audebertet al. The 66th ASH Annual Meeting, Dec 2024, San Diego (CA), United States. 144 (Supplement 1), pp.4097-4097, 2024, ⟨10.1182/blood-2024-200580⟩ Poster de conférence hal-05390918v1

Brevet (1)

New use of ironomycine on AML Raphaël Rodriguez,Tatiana Cañeque,Mark A Dawson,Sylvain Garciaz France, Patent n° : 20305750. 2020 Brevet hal-04069933v1